• TACTIC-E Trial
• Immunomodulatory agents • Multi-arm randomized trial
• Pre-intensive care unit (ICU) COVID-19 patients
• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care
• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days
• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)